Article ; Online: Case-Control Study of Individuals With Small Fiber Neuropathy After COVID-19.
Neurology(R) neuroimmunology & neuroinflammation
2024 Volume 11, Issue 3, Page(s) e200244
Abstract: Objectives: To report a case-control study of new-onset small fiber neuropathy (SFN) after COVID-19 with invasive cardiopulmonary exercise testing (iCPET). SFN is a critical objective finding in long COVID and amenable to treatment.: Methods: A ... ...
Abstract | Objectives: To report a case-control study of new-onset small fiber neuropathy (SFN) after COVID-19 with invasive cardiopulmonary exercise testing (iCPET). SFN is a critical objective finding in long COVID and amenable to treatment. Methods: A retrospective chart review was conducted on patients seen in the NeuroCOVID Clinic at Yale who developed new-onset SFN after a documented COVID-19 illness. We collected demographics, symptoms, skin biopsy, iCPET testing, treatments, and clinical response to treatment or no intervention. Results: Sixteen patients were diagnosed with SFN on skin biopsy (median age 47, 75% female, 75% White). 92% of patients reported postexertional malaise characteristic of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and 7 patients underwent iCPET, which demonstrated neurovascular dysregulation and dysautonomia consistent with ME/CFS. Nine patients underwent treatment with IVIG, and 7 were not treated with IVIG. The IVIG group experienced significant clinical response in their neuropathic symptoms (9/9) compared with those who did not receive IVIG (3/7; Discussion: Here, we present preliminary evidence that after COVID-19, SFN is responsive to treatment with IVIG and linked with neurovascular dysregulation and dysautonomia on iCPET. A larger clinical trial is indicated to further demonstrate the clinical utility of IVIG in treating postinfectious SFN. Classification of evidence: This study provides Class III evidence. It is a retrospective cohort study. |
---|---|
MeSH term(s) | Humans ; Female ; Middle Aged ; Male ; Small Fiber Neuropathy ; Case-Control Studies ; Retrospective Studies ; Fatigue Syndrome, Chronic ; Post-Acute COVID-19 Syndrome ; Immunoglobulins, Intravenous ; COVID-19 ; Autonomic Nervous System Diseases |
Chemical Substances | Immunoglobulins, Intravenous |
Language | English |
Publishing date | 2024-04-17 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2767740-0 |
ISSN | 2332-7812 ; 2332-7812 |
ISSN (online) | 2332-7812 |
ISSN | 2332-7812 |
DOI | 10.1212/NXI.0000000000200244 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.